ModraDoc006/r
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Key Facts
About Modra Pharmaceuticals
Modra Pharmaceuticals is a clinical-stage biotech company developing oral formulations of widely used intravenous taxane chemotherapies. Its proprietary technology platform combines optimized, water-soluble taxane tablets with a pharmacokinetic booster (ritonavir) to overcome poor oral bioavailability and enhance drug exposure. The company's lead program, ModraDoc006/r, is in Phase 2b development for metastatic castration-resistant prostate cancer (mCRPC), with the goal of offering equivalent efficacy with improved tolerability and a more convenient, patient-friendly administration. Founded as a spin-out from the Netherlands Cancer Institute, Modra is positioning itself to address a significant unmet need in the standard oncology care paradigm.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| SYNC-T | Syncromune | Phase 2 |